W-135 and Y conjugate vaccine
Sponsors
Moderna Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline Biologicals, Sanofi Pasteur, Sanofi Pasteur Inc.
Conditions
Acute lower respiratory infectionC3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)Generalized Myasthenia GravisGeneralized Myasthenia Gravis and Ocular Myasthenia GravisHealthy infants receiving a profylactic vaccine to prevent measles infectionHealthy volunteers (Meningococcal infection)InfectionsInvasive meningococcal disease
Phase 1
A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 months to < 24 months
CompletedCTIS2022-502022-41-00
Start: 2024-05-28End: 2024-12-18Target: 248Updated: 2024-09-24
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine when Administered to Healthy Infants
CompletedCTIS2023-506449-40-00
Start: 2021-11-29End: 2025-11-21Target: 497Updated: 2025-09-01
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Not yet recruitingCTIS2025-522406-20-00
Target: 51Updated: 2026-02-18
Phase 2
A PHASE 2, RANDOMIZED, BLINDED, PLACEBOCONTROLLED, STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOMETRICS, AND EFFICACY OF DNTH103 IN ADULTS WITH GENERALIZED MYASTHENIA GRAVIS (MAGIC)
RecruitingCTIS2024-512865-15-00
Start: 2024-09-03Target: 54Updated: 2025-10-27
A parallel-group prevention, Phase II, partially blinded, multi-stage study to investigate the immunogenicity and safety of Pentavalent Meningococcal ABCYW Vaccine formulations compared with licensed meningococcal vaccines when administered alone in healthy children (2 to 9 years of age) or concomitantly with routine pediatric vaccines in toddlers (12 to 15 months of age) and infants (2 months of age).
Active, not recruitingCTIS2023-510465-10-00
Start: 2025-03-10Target: 250Updated: 2025-11-13
Phase 3
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (VALE)
Active, not recruitingCTIS2023-504625-39-00
Start: 2023-05-18Target: 66Updated: 2026-01-08
A parallel-group, prevention, Phase III, modified double-blind, 2-arm, study to investigate the immunogenicity and describe the safety of a quadrivalent meningococcal conjugate vaccine (MenACYW conjugate vaccine) compared with Nimenrix® when administered in a 1+1 schedule in healthy infants and toddlers at 6 and 12 months of age
RecruitingCTIS2023-508177-85-00
Start: 2024-03-12Target: 840Updated: 2026-01-26
Phase 4
Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in the elderly population
Active, not recruitingCTIS2024-513640-29-00
Start: 2024-05-13Target: 280Updated: 2025-10-27
EarLy extra Measles immunisation during a measles Outbreak (ELMO)
Not yet recruitingCTIS2024-513395-18-00
Target: 155Updated: 2024-07-22